Sangamo Therapeutics Appeals Delisting While Advancing ST-920 Submission

Sangamo Therapeutics is preparing to submit its Biologics License Application (BLA) for ST-920 as early as this summer. Concurrently, the company is appealing a NASDAQ delisting decision made in June.